U.S. Patent No. 10,512,629 B1 (‘629) issued on December 24, 2019, entitled ”Compositions Comprising a Cannabinoid and Spilanthol.” It was issued to inventor Zohar Koren of Gan Ner, Israel. The applicant/assignee is SciCann Therapeutics, Inc., of Toronto, Canada.
The specification discloses fixed-dose combination (FDC) therapeutic compound of one cannabinoid and spilanthol for treatment of various inflammatory diseases. Various embodiments include any species of Cannabis, including C. sativa, C. indica, and C. ruderalis. Other embodiments include one species from any of the following genera: Heliopsis, Acmella, or Wedelia. The ‘629 claims are directed to a method of treatment of non-alcoholic steatohepatitis, a type of nonalcoholic fatty liver disease (NAFLD), comprising a dosing administration of at least 95% pure cannabidiol (CBD) and at least 95% pure spilanthol, with further limitations for a CBD amount of between 5 to 500 mg, and spilanthol amount of between 1 to 100 mg.
Fig. 8A illustrates the claimed invention:
The Cooperative Patent Classification is A61K, preparations for medical, dental, or toilet purposes, namely, (36/00), medical preparations containing organic active ingredients, namely, condensed with carbocyclic rings (31/352), and amides, e..g, hydroxamic acids (31/16), and A61P, specific therapeutic activity of chemical compounds or medicinal preparations, namely, drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g., hepatoprotective agents, cholagogues, litholytics (1/16).
SciCann Therapeutics is a privately-owned Canadian-Israeli joint venture focused on medical cannabis research in oncological and neurodegenerative diseases and inflammatory disorders. Israel is leading the world efforts in cannabis medical research. Please contact Yonaxis for more information or if you have any questions.